Compugen Ltd.
NASDAQ:CGENBiotechnology
+$0.01 today
- Market cap
- $185.66M
- Beta
- 2.74
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.37
Volume 0.15M
Average 0.48M
CGEN Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Compugen Ltd.NASDAQ: CGEN
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $1.35M rose 8.7% year over year, ahead of the -19.6% change in trailing-twelve-month other income / expenses. Sequentially, it rose 68.7% from the prior quarter. Over 3 fiscal years it compounded at +32.8% a year.
Context
- Other income / expenses amounted to 5.6% of revenue in FY2025, down 13.0 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +8.7% holds above the trailing-twelve-month pace of -19.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 4.07M USD
- Year-over-year change
- -21.4%
- 4-year CAGR
- +47.0%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.07M | -21.4% |
| FY2024 | 2024-12-31 | 5.18M | +61.5% |
| FY2023 | 2023-12-31 | 3.21M | +84.6% |
| FY2022 | 2022-12-31 | 1.74M | +99.5% |
| FY2021 | 2021-12-31 | 871K | — |
Other Income / Expenses vs competitors
How CGEN compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -19.6% is the 6th highest of 9, against a peer median of +5.5%.
- Other income / expenses amounts to 5.8% of revenue for CGEN, versus a peer median of 152.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.31M USD | -38.1% | — | — | |
| FY2025 | €4.25M EUR | +101.9% | — | 152.4% | |
| LTM Mar 2026 | $4.18M USD | -19.6% | +32.8% | 5.8% | |
| LTM Mar 2026 | $3.8M USD | +106.4% | -3.5% | 21.6% | |
| LTM Mar 2026 | $2.67M USD | -17.9% | +37.4% | 507.8% | |
| LTM Mar 2026 | $1.11M USD | +28.9% | +96.6% | — | |
| LTM Mar 2026 | -$1.59M USD | +51.0% | — | 50.2% | |
| LTM Mar 2026 | -$3.08M USD | -1482.5% | — | 172.8% | |
| LTM Mar 2026 | -CHF 6.37M CHF | -427.8% | — | — | |
| Peer median (excluding CGEN) | — | +5.5% | +37.4% | 152.4% | |
Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6M | 7.5M | 33.46M | 27.86M | 72.76M |
| Cost of Revenue | 680K | 975K | 2M | 7.93M | 9.25M |
| Gross Profit | 5.32M | 6.53M | 31.46M | 19.93M | 63.51M |
| Gross Margin | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| Research & Development | 28.69M | 30.65M | 34.47M | 24.81M | 22.76M |
| Selling, General & Admin | 11.7M | 11.25M | 9.98M | 10.02M | 9.43M |
| Operating Expenses | 40.39M | 41.9M | 44.45M | 34.83M | 32.19M |
| Depreciation & Amortization | 461K | 482K | 476K | 486K | 475K |
| EBITDA | (33.72M) | (33.13M) | (9.28M) | (9.19M) | 35.87M |
| EBITDA Margin | -562.0% | -441.7% | -27.7% | -33.0% | 49.3% |
| Operating Income | (35.07M) | (35.37M) | (12.99M) | (14.89M) | 31.33M |
| Operating Margin | -584.6% | -471.7% | -38.8% | -53.4% | 43.1% |
| Interest Income | 894K | 1.44M | 3.24M | 5.24M | 4.41M |
| Interest Expense | 25K | 27K | 31K | 34K | 0 |
| Other Income / Expenses | 871K | 1.74M | 3.21M | 5.18M | 4.07M |
| Income Before Tax | (34.2M) | (33.64M) | (9.78M) | (9.71M) | 35.4M |
| Pre-Tax Margin | -570.0% | -448.5% | -29.2% | -34.8% | 48.6% |
| Income Tax Expense | 0 | 58K | 8.97M | 4.52M | 54K |
| Net Income | (34.2M) | (33.69M) | (18.75M) | (14.23M) | 35.34M |
| Net Margin | -570.0% | -449.3% | -56.1% | -51.1% | 48.6% |
| EPS (Basic) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 |
| EPS (Diluted) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 |
| Weighted Avg Shares | 84.2M | 86.56M | 87.63M | 89.53M | 93.43M |
| Weighted Avg Shares (Diluted) | 84.2M | 86.56M | 87.63M | 89.53M | 93.82M |
Compugen Ltd.
NASDAQ:CGEN
Intrinsic Alpha fair value
Locked
Current Price
$1.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.